Cowen & Co. analyst Ritu Baral downgrades Aptinyx (NASDAQ:APTX) from Outperform to Market Perform.
BIOLASE Inc. Announces Pricing Of $4.5M Underwritten Public Offering Of Series H Convertible Redeemable Preferred Stock and Warrants
BIOLASE, Inc. (NASDAQ:BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the pricing of an underwritten public offering of 175,000 units (the